Dirui Industrial Co (300396) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥878.27 million, up 26.38% year-over-year, with net profit attributable to shareholders at ¥165.24 million, a 2.12% increase compared to the same period last year.

• The company maintained strong R&D investment, launching new products and expanding its patent portfolio to 211 patents, including 138 invention patents.

• Domestic market focus led to over 1,000 key instrument installations and more than 220 window hospital partnerships; international reagent sales grew over 20%.

• The company operates in the rapidly growing in-vitro diagnostics (IVD) sector, benefiting from favorable policies, domestic substitution, and equipment renewal trends.

Financial highlights

• Operating income rose 26.38% year-over-year to ¥878.27 million; net profit attributable to shareholders increased 2.12% to ¥165.24 million.

• Gross margin declined by 6.47 percentage points to 43.18% due to higher instrument sales with lower margins.

• Operating cash flow was negative at -¥287.72 million, mainly due to collection cycle changes, with expectations for recovery in H2.

• R&D expenses increased 44.37% year-over-year to ¥69.19 million, reflecting ongoing innovation efforts.

• Total assets at period-end were ¥3.04 billion, down 8.32% from year-end 2023; net assets attributable to shareholders rose 1.47% to ¥2.07 billion.

Outlook and guidance

• The company expects continued growth driven by domestic substitution, policy support for equipment renewal, and expansion in both domestic and international markets.

• Focus remains on product innovation, intelligent laboratory solutions, and strengthening sales channels.